Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
MRVI Maravai LifeSciences
14.660+0.250+1.73%
Close
01/31 16:00 ET
14.6600.0000.00%
Pre Mkt Price 02/01 04:00 ET
High
14.730
Open
14.690
Turnover
12.52M
Low
14.375
Pre Close
14.410
Volume
859.31K
Pre-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
5 Value Stocks In The Healthcare Sector
Understanding Value StocksA value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indica
Ardevora Asset Management LLP Sells 805,791 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Ardevora Asset Management LLP reduced its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) by 47.1% in the third quarter, according to its most recent Form 13F fi
US Bancorp DE Sells 31,254 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
US Bancorp DE cut its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) by 59.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exc
Maravai LifeSciences (NASDAQ:MRVI) Price Target Cut to $16.00
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) had its target price reduced by analysts at The Goldman Sachs Group from $18.00 to $16.00 in a note issued to investors on Tuesday, Benzinga reports.
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Maravai Lifesciences Holdings (MRVI)
Maravai LifeSciences Is Maintained at Buy by Goldman Sachs
Maravai LifeSciences Price Target Cut to $16.00/Share From $18.00 by Goldman Sachs
Maravai LifeSciences Price Target Cut to $16.00/Share From $18.00 by Goldman Sachs
Goldman Sachs Maintains Buy on Maravai LifeSciences, Lowers Price Target to $16
Goldman Sachs analyst Matthew Sykes maintains Maravai LifeSciences with a Buy and lowers the price target from $18 to $16.
Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) was the recipient of some unusual options trading activity on Wednesday. Investors purchased 1,002 put options on the company. This is
Maravai LifeSciences Downgraded to Neutral at UBS on Lack of Near-term Catalyst
Company Overview
More
Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The Protein Detection segment is engaged in manufacturing and selling labeling and visual detection reagents to scientific research customers for their tissue-based protein detection and characterization needs. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
CEO： Mr. Carl W. Hull
Market： NASDAQ
Listing Date： 11/20/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet